US Stock Market Closed

Dashboard

Emergent BioSolutions, Inc. (EBS)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

B

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

CEO

Robert G. Kramer

Employees

1,834

Industry

Diversified Biopharmaceuticals

Sector

Healthcare

Headquarters

Gaithersburg

Exchange

New York Stock Exchange

Summary Stats

Market Cap

1.64B

Revenue

1.76B

Net Income

158M

EPS

$2.96

Price-to-Earnings

11.03

Price-to-Book

1.04

Debt-to-Equity

0.77

News

Analyst Ratings

Price targets projected by 7 analysts

High

$144.00

Average

$111.29

Low

$86.00

Ratings calculated by 8 analysts

Buy

6

Hold

2

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Above by $0.06

Actual

$0.18 +50.0%

Consensus

0.12

Report Date

Year Ago

1.53

Year Ago Change %

Down 88%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites